Big announcement
1. NIO's Q4 revenue was 17.103 billion yuan, up 6.5% year-on-year
$NIO-SW (09866.HK)$Q4 revenue was 17.103 billion yuan, up 6.5% year on year, and net loss was 5.367.7 billion yuan, down 7.2% year on year. The number of cars delivered during the period reached 50,000, an increase of 25% over the previous year. Total revenue in 2023 was 55,617.9 billion yuan, up 12.9% year on year, and net loss was 21.147 billion yuan, up 45.25% year on year; vehicle deliveries reached 160,000 vehicles in 2023, up 30.7% year on year. Delivery volume in Q1 is expected to be 31,000 to 33,000 vehicles in 2024, and the market expects 44,035 vehicles.
2. Great Wall Motor: Total sales volume in February was 71,027 units, up 4.12% year on year
$GWMOTOR (02333.HK)$According to the announcement, in February 2024, car sales volume was 71,000 units, up 4.12% year on year; automobile production was 62,000 units, down 17.64% year on year. From January to February 2024, automobile sales were 175,200 units, up 34.91% year on year; automobile production was 157,800 units, up 21.34% year on year.
3. The total consolidated electricity sales volume of China Electric Power in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year
$CHINA POWER (02380.HK)$According to the announcement, the group's total consolidated electricity sales volume in January 2024 was 10.3482 million megawatt-hours, an increase of 41.15% over the same period last year.
4. Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed generic drug consistency evaluation
$SH PHARMA (02607.HK)$According to the announcement, Shanghai Hefeng Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Pharmaceutical Group Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration for norepinephrine bitartrate injections. The drug passed the consistent evaluation of generic drug quality and efficacy. Norepinephrine bitartrate injections are mainly used for blood pressure control in certain acute hypotensive states.
Earnings Report
$BANK OF TIANJIN (01578.HK)$2023 net profit of 3.77 billion yuan increased 5.7% year-on-year
$HUTCHTEL HK (00215.HK)$2023 revenue of HK$4.896 billion with final interest of HK5.21 cents per share
$YUEXIUTRANSPORT (01052.HK)$: Profit attributable to shareholders in 2023 was 765 million yuan, up 68.9% year-on-year
$MEDBOT-B (02252.HK)$Revenue is expected to increase by more than 350% year over year in 2023
$MICROPORT (00853.HK)$Fa Ying Con expects a loss of no more than US$580 million in 2023
Operational data
$GREENTOWN CHINA (03900.HK)$The total contract sales amount for the first two months was about 24.9 billion yuan
$SUNAC (01918.HK)$: The contract sales amount was about 2.73 billion yuan in February
$TRULY INT'L (00732.HK)$: Consolidated net turnover of approximately HK$1,142 billion in February
$KWG GROUP (01813.HK)$The pre-sale amount for February was 620 million yuan
$CONCORD NE (00182.HK)$Total equity power generation in February was 872.28 GWh, up 46.32% year-on-year
Pharmaceutical Innovation
$TONG REN TANG (01666.HK)$: Obtained approval notice for clinical trials of Astragalus ginseng granules
Equity incentives
$PACIFIC BASIN (02343.HK)$The grant involved a total of 18.079 million bonus shares
$CLOUD MUSIC (09899.HK)$1.34 million award shares were granted to 371 employee participants
Repurchase cancellation
$AIA (01299.HK)$5.194 million shares were repurchased at HK$318 million on March 5
$HSBC HOLDINGS (00005.HK)$On March 4, it cost HK$172 million to repurchase 2,836,000 shares
$STANCHART (02888.HK)$On March 4, £185.693 million was spent to buy 2,713,200 shares
$YUM CHINA (09987.HK)$On March 4, it cost 18.6 million US dollars to buy back 444,500 shares
$KUAISHOU-W (01024.HK)$On March 5, 915,000 shares were repurchased at HK$39.92 million
$SWIRE PACIFIC A (00019.HK)$On March 5, it spent HK$19.165 million to repurchase 307,000 shares
$ASCLETIS-B (01672.HK)$3.06 million shares cancelled on March 5
edit/ruby